| Name | Title | Contact Details |
|---|
UNITED STATES ENDOSCOPY GROUP is a Mentor, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HCSG is a Levittown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tobii Dynavox, a wholly owned subsidiary of Tobii AB (publ), is the leading global provider of eye tracking enabled and touch-based augmented and alternative communication (AAC) devices as well as symbol-based products for individuals with special needs.
At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.